Print

P53 and Bcl 2 Expression in Breast Cancer. Prospective Study in Tunisia

Issue: Vol.2, No.2 - January 2003

« Back to Articles

Article Type: Manuscript

Download PDF Version »

  1. Mrs Fourati- Kharrat
    Service Immuno-Histo-Cytologie, Place Bad Saadoun, 1006 Tunis, Tunisia
  2. S Bouraoui
  3. K Rahal
  4. A Gamoudi
  5. M V El May
  6. N Mokni
  7. A El May
  8. M Ben Abdallah

Aim: Bc12 and P53 genes products continue to be extensively studied in breast cancer in order to identify factors and to optimise therapeutic approaches. We evaluated p53 and bc12 immuno-reactivity in 72 Tunisian breast cancers.

Methods and results: a total of 72 paraffin-embedded tumors were evaluated for nuclear p53 and cytoplasmic bc12 immuno-reactivity. The results were semi-quantitated. The P53 over-expression was seen in 65% of cases, and was significantly associated with high histological grade (p < 0.001), and correlated inversely to bcl2 (p = 0.02). Bcl2 expression was observed in 54% of cases. No correlation was seen between bcl2 expression and classic prognostic factors.

Conclusion: in breast cancer P53 over-expression appears to be indicative of biologic aggressiveness and p53 accumulation reduces expression of bcl2 in tumors.

Download PDF Version »

Favourites   Share / Bookmark

Also In This Issue

« Back to Articles